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ABSTRACT
Ewing sarcoma (ES) involves a tumor-specific chromosomal translocation that 
produces the EWS-FLI1 protein, which is required for the growth of ES cells both 
in vitro and in vivo. However, an EWS-FLI1-driven transgenic mouse model is not 
currently available. Here, we present data from six independent laboratories seeking 
an alternative approach to express EWS-FLI1 in different murine tissues. We used 
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INTRODUCTION
Ewing sarcoma (ES) is a highly malignant tumor of 
bone and soft tissue that occurs in children, adolescents, 
and young adults. Tumors often grow in close proximity 
to bone but can occur as soft tissue masses [1-3]. ES cases 
show a balanced chromosomal translocation [4] that joins 
the EWS gene (EWing Sarcoma) located on chromosome 
22 to an ETS family gene, which is most commonly either 
FLI1 (Friend Leukemia Insertion) located on chromosome 
11, t(11;22) or ERG located on chromosome 21, t(21;22). 
The resulting fusion protein is termed EWS-FLI1 or EWS-
ERG, respectively. Other infrequent variant fusion proteins 
are the products of ES translocations and are absent in 
non-tumor cells. FLI1 is an ETS family transcription 
factor with a conserved DNA binding domain. The 
carboxy terminal half of FLI1 contained in the EWS-FLI1 
fusion protein retains its DNA binding domain. Therefore, 
EWS-FLI1 binds to DNA through the conserved ETS 
binding domain. However, the EWS-FLI1 fusion protein 
functions by a different mechanism than either EWS or 
FLI1 [5]. EWS-FLI1 is required to maintain the growth of 
ES cell lines, and when the expression level of EWS-FLI1 
is reduced by alternative mechanisms, ES cell lines die in 
culture and xenografts in nude mice regress [6-13]. 
While the oncogenic activity of EWS-FLI1 is clear, 
the cell of origin for ES has been confounding due to the 
cytotoxic effects of expressing EWS-FLI1 in most primary 
cell types [14-16]. Previous studies have identified three 
primary cell types that are permissive for EWS-FLI1 
expression and thus represent prime candidates for the 
elusive tumor cell of origin: (i) mesenchymal stem cells 
(MSCs) [17-19], (ii) neural crest stem cells [20], and (iii) 
embryonic osteochondrogenic progenitor cells [21].
Transgenic mouse models have been successfully 
developed for neoplasms with tumor-specific 
chromosomal translocations, including alveolar 
rhabdomyosarcoma, synovial sarcoma, myxoid 
liposarcomas, and clear cell sarcomas [22-27]. However, 
the same success has not been achieved in ES. When 
EWS-FLI1 was expressed ubiquitously under the native 
EWS promoter, either in utero or in adult mice, it resulted 
in lethality [16]. Because EWS-FLI1 induces apoptosis 
in mouse embryonic fibroblasts in vitro, the embryonic 
lethality resulting from broad transgenic expression was 
not surprising. When the expression of EWS-FLI1 was 
restricted to specific cell types, the animals survived but 
did not develop ES. EWS-FLI1 expression under the 
control of the Prx1 promoter resulted in developmental 
malformations in the limbs, but not tumor formation 
[28]. When these animals were crossed with p53 null 
mice, EWS-FLI1 expression accelerated the p53 null-
induced formation of osteosarcoma and shifted the tumor 
histology from osteosarcoma to undifferentiated sarcoma. 
Moreover, EWS-FLI1 expression under the control of 
the Mx1 promoter resulted in the rapid development of 
myeloid/erythroid leukemia [29]. The Prx-1 promoter 
is active in the primitive mesenchyme of the early limb 
bud, while the Mx1 promoter is active in liver, spleen, 
bone marrow, and lymphoid tissues following induction 
with type I interferon (IFNα/β). A more recent attempt to 
create an ES transgenic mouse model utilized Cre-loxP-
mediated somatic chromosomal translocation between 
the EWS and FLI1 locus to express the fusion protein 
in vivo [30]. However, this strategy did not lead to any 
malignant neoplasms; instead, the mice presented with 
cardiomyopathy followed by death [30].
Experimental ES models consist of murine 
xenografts from established human ES cell lines or as 
allografts of mouse bone marrow-derived mesenchymal 
progenitors transfected with EWS-FLI1 [17, 19, 21, 31, 
32]. The expression of EWS-FLI1 in zebrafish also results 
in tumor formation, with higher incidences on the p53 
null background [33]. However, these models lack the 
essential elements of tumor initiation, as they are derived 
from established tumors or cell lines transformed in 
vitro. Therefore, these models do not fulfill the need for a 
transgenic mouse that develops spontaneous ES driven by 
EWS-FLI1 expression.
RESULTS
To develop a clinically relevant ES mouse model 
for use in studying disease pathogenesis and testing novel 
therapies, we employed transgenic and non-transgenic 
approaches to express an EWS-FLI1 transgene in different 
tissues at different times. Overall, 16 alternative methods 
were tried in 6 independent laboratories (Table 1). For 
simplicity of discussion, these models will be referred to 
by the numbers provided in Table 1 in this manuscript. 
the Runx2, Col1a2.3, Col1a3.6, Prx1, CAG, Nse, NEFL, Dermo1, P0, Sox9 and Osterix 
promoters to target EWS-FLI1 or Cre expression. Additional approaches included 
the induction of an endogenous chromosomal translocation, in utero knock-in, and 
the injection of Cre-expressing adenovirus to induce EWS-FLI1 expression locally 
in multiple lineages. Most models resulted in embryonic lethality or developmental 
defects. EWS-FLI1-induced apoptosis, promoter leakiness, the lack of potential 
cofactors, and the difficulty of expressing EWS-FLI1 in specific sites were considered 
the primary reasons for the failed attempts to create a transgenic mouse model of ES.
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Table 1: A summary of sixteen approaches employed by six independent laboratories to express an EWS-FLI1 
transgene in mice.
Model # Target tissue Promoter Time of expression Inducible? Phenotype Lab 
#1
Runx2Cre-EF
Osteoblast 
precursor
Cre under Runx2 prom.
EWS-FLI1 under 
Rosa26 prom 
Embryonal  
(E12.5) No
No phenotype in two clones 
on WT or INK4a/ARF-/- 
background.
Embryonic lethality (E13.5) 
in one clone. 
Moriggl
# 2
OsxCre-EF
Osteoblast 
precursor
Cre under Osterix1 
prom.
EWS-FLI1 under 
Rosa26 prom.
Embryonal  
(E14.5) or 3 
weeks old 
Yes (Tet-off for 
Cre expression)
Embryonal: Lethal
3 weeks : Facial deformities 
on WT p53 and Rb
3 weeks: Leukemia and 
reduced osteosarcoma in 
p53-/-Rb-/- background.
Üren
#3
Col1a2.3Cre-EF 
and Col1a3.6Cre-
EF
Osteoblasts
Cre under Col1a2.3 or 
Col1a3.6 prom.
EWS-FLI1 under EWS 
prom.
Embryonal  
(E18.5) No Embryonic lethal Lee
# 4
Cosco-EF Ubiquitous
EWS-FLI1 under EWS 
prom. Embryonal No Embryonic lethal Delattre
#5
Pgk-EF Ubiquitous 
EWS-FLI1 under Pgk 
prom. Embryonal No Embryonic lethal Delattre
# 6
Nse-EF and Nse-
EF-SV
Neuronal tissue EWS-FLI1 under Nse prom. Embryonal No Embryonic lethal Delattre
# 7
NEFL-EF Neuronal tissue
EWS-FLI1 under 
dNEFL prom. Adult No
EWS-FLI1 expressed in 
adult brain and cerebellum 
but no tumor
Delattre
# 8
MT-EF Ubiquitous 
EWS-FLI1 under 
Metallothionein prom. Variable 
Yes (ZnCl2 
for EWS-FLI1 
expression)
No phenotype Delattre
# 9
PLAPtTA-EF Ubiquitous
tTA under PLAP prom.
EWS-FLI1 under 
hCMV-TRE prom. 
Embryonal
Yes (Tet-off 
for EWS-FLI1 
expression)
Embryonic lethal Delattre
#10
COMET and 
COMETΔNeo
Ubiquitous EWS-FLI1 under TRE
tight 
prom. Variable 
Yes (Tet-on for 
EWS-FLI1-
luciferase 
expression)
EWS-FLI1 toxicity during 
spermatogenesis in chimera 
mice, no F1 KI progeny.
Delattre 
#11
Prx1Cre-EF
Limb bud 
Mesenchyme
Cre under Prx1 prom.
EWS-FLI1 under EWS 
prom.
Embryonal  
(E9.5) No Embryonic lethal Lee
#12
Cre-TL-EF
Mesenchymal 
and neural crest 
tissue
Cre under Dermo1, Prx1, 
P0, Col1a2, or Sox9 
prom.
EWS-FLI1 under EWS 
prom.
Embryonal No No phenotype on WT or INK4a/ARF-/- background
Sweet-
Cordero
#13
RetroLTR-EF
Mesenchymal 
stem cells
EWS-FLI1 under 
Retroviral LTR Adult No Fibrosarcoma Nakamura 
#14
piggyBac-EF
Mesenchymal 
stem cells
EWS-FLI1 under CMV 
prom. Adult No Fibrosarcoma Nakamura 
#15
CreEP-TL-EF
Not-tissue 
selective. 
Cre injected IM
Cre under pMC1 prom.
EWS-FLI1 under EWS 
prom.
4 weeks old No Muscle degeneration Nakamura 
#16
Ad5Cre-EF
Not-tissue 
selective. Virus 
injected IM, IP 
and IV
Cre under Ad5-CMV 
prom.
EWS-FLI1 under 
Rosa26 prom.
1 day old 
1 week old 
3 weeks old 
No
IV: No phenotype 
IP: Developmental 
defects in intestines 
IM: Muscle atrophy 
Üren 
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Transgenic approaches: bone and bone precursors
EWS-FLI1 expression in osteoblast precursors via the 
Runx2 promoter (Model #1Runx2Cre-EF) 
Runx2 is a master transcription factor for 
chondrocyte and osteoblast differentiation that regulates 
bone formation [34]. We established a conditional EWS-
FLI1 mouse model in which the expression of the fusion 
protein was controlled by Cre recombinase driven by the 
Runx2 promoter in a 150 kB BAC transgene encompassing 
the Runx2 gene. Here, an improved Cre codon sequence 
was inserted into the coding exon adjacent to the START 
codon to drive expression from the bone-specific distal 
promoter [35] (Supplementary Figure S1). Cre-inducible 
ROSA26-loxP-STOP-loxP-EWS-FLI1 (E/F) mice [29], 
in which EWS-FLI1 is under control of the ROSA26 
gene locus, were used. Therefore, EWS-FLI1 could be 
ubiquitously expressed following the removal of the STOP 
codon by Cre recombinase. To restrict and target EWS-
FLI1 expression to the bone-forming lineage, E/F mice 
were crossed to Runx2-Cre mice. We used three different 
characterized Runx2-Cre transgenic mouse lines (#777, 
#784 and #1634) that gave different phenotypes. The 
highest Cre recombinase expression was observed in line 
#777 compared to lines #784 and #1634 [35]. 
An analysis of the tissues from E/F mice crossed 
with the #784 and #1634 Runx2-Cre transgenic lines (E/
F+/-Runx2-Cre+ mice) showed Cre activity in the bone, 
bone marrow, calvaria, and testis (Supplementary Figure 
S2A). Offspring from these mice were viable and fertile 
(Supplementary Table S1). Careful and regular phenotype 
screening over 18 months did not reveal any obvious gross 
abnormalities or tumor formation. The excision of the 
STOP-cassette in the bone, testis, and isolated osteoblasts 
was confirmed by genomic PCR (Supplementary Figure 
S2B). However, EWS-FLI1 could not be detected at the 
mRNA level (Supplementary Figure S3A). We failed to 
detect EWS-FLI1 expression in compound animals of the 
#784 E/F+/- Runx2-Cre+ and #1634 E/F+/- Runx2-Cre+ lines. 
We also noted the loss of Cre expression in compound 
mesenchymal tissue, although Cre was well expressed in 
mice without the E/F transgene (Supplementary Figure 
S4). In order to confirm that the EWS-FLI1 locus was 
amenable to Cre-induced recombination, we isolated 
ear skin fibroblasts from these lines and expressed Cre 
recombinase using an adenoviral delivery system in cell 
culture (Supplementary Figure S5). 
Crossing E/F mice with the #777 Runx2-Cre 
transgenic line resulted in early embryonic lethality 
around embryonic day 13.5 (E13.5), and no transgenic 
offspring could be generated (Supplementary Table S1). 
We hypothesized that EWS-FLI1 protein expression 
in the target tissues of the #777 Runx2-Cre line caused 
developmental problems that led to embryo resorption 
before E13.5 (two litters with 13 embryos were analyzed 
from E/F+/+ female versus the #777 Runx2-Cre male 
cross), which thereby excluded the usefulness of that 
model. We did not further trace the cause of death. Twelve 
litters of offspring from that cross were analyzed further. 
While genetic PCR showed that these offspring carried the 
E/F transgene, no #777 Runx2-Cre expression in parallel 
could be detected, suggesting negative selection and the 
loss of double transgenic embryos during early embryonic 
development. 
EWS-FLI1 has a growth inhibitory effect in most 
primary cells, and the loss of p16INK4a enables the cells to 
tolerate EWS-FLI1 expression in vitro [14]. Therefore, 
we postulated that the lethal effect of EWS-FLI1 on 
Runx2-Cre-expressing cells could be relieved by deleting 
the p16ink4a locus. Moreover, the loss of p16INK4a is a 
relatively common event in ES [36]. Thus, we crossed E/
F+/- Runx2-Cre+ mice (both #784 and #1634 lines) to an 
Ink4a-deficient background. The offspring of these mice 
were viable (Supplementary Table S1), and a careful 
analysis of these E/F+/- Runx2-Cre+ Ink4a-/- compound 
mice showed the same lack of EWS-FLI1-expressing 
offspring as seen in the E/F+/- Runx2-Cre+ mice. The 
deletion of the STOP-cassette was confirmed in the 
bone and testis, but no expression of EWS-FLI1 could 
be observed (Supplementary Figure S6). Ink4a-/- mice 
are prone to tumor formation of mainly fibrosarcoma, 
liposarcoma, angiosarcoma and lymphomas [37]. We 
observed 30 mice per genotype over 12 months and did not 
detect any changes in the frequency or histopathological 
type of tumors in E/F+/- Runx2-Cre+ Ink4a-/- compared to 
Ink4a-/- mice. Often, multiple different tumors occurred 
in single animals. However, we evaluated more than 10 
tumors isolated from the different genotypes and could 
not detect Cre or EWS-FLI1 expression in any of them. 
Therefore, we concluded that the toxic effect of EWS-
FLI1 expression could not be rescued by the loss of Ink4a 
protein. 
EWS-FLI1 expression in osteoblast precursors via the 
Osterix-1 promoter (Model #2OsxCre-EF)
Considering that most ES cases develop in bone or 
in close proximity to the bone, we hypothesized that the 
targeted expression of EWS-FLI1 in osteoblast progenitors 
may induce ES. Osterix (Osx) is a zinc finger-containing 
transcription factor required for osteoblast differentiation 
[38], and the promoter restricts Cre expression to the 
osteoblast lineage [39]. We expressed EWS-FLI1 in 
osteoblast progenitors by crossing E/F mice with inducible 
Tet-Off-based Osx-Cre mice (Supplementary Figure S7). 
The expression of EWS-FLI1 in E/F+/- Osx-Cre+ mice 
with wild-type (WT) p53 and Rb was embryonically 
lethal. Thus, we delayed Cre expression, and hence EWS-
FLI1 expression, until weaning, upon which 32.6% of 
these mice developed evident facial bone deformities 
at the age of 5-6 months (Figures 1A and 1B). Osx-
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Cre-mediated deletion of p53 and Rb in both Osx-Cre+ 
p53fl/+ pRbfl/+ and Osx-Cre+ p53fl/fl pRbfl/fl mice resulted 
in osteosarcoma, and the latency of the disease could be 
delayed using a doxycycline diet [40]. When we crossed 
E/F mice with Osx-Cre+ p53fl/fl pRbfl/fl mice, we observed 
embryonic lethality. The administration of doxycycline 
to pregnant mothers was required for viable births. When 
the EWS-FLI1 expression was delayed until weaning, 
E/F+/- Osx-Cre+ p53fl/+ pRbfl/+ mice did not develop 
sarcoma; instead, 45.2% of these mice presented with 
leukemia (Figures 1C and 1D). We confirmed EWS-FLI1 
expression in the spleens and livers of these leukemic 
mice at the mRNA and protein levels (Supplementary 
Figures S8A and B). Immunophenotyping suggested that 
the leukemia in Osx-Cre+ p53fl/+ pRbfl/+ mice was similar 
to the previously reported EWS-FLI-induced erythroid/
myeloid leukemia, in which EWS-FLI1 expression was 
driven by Mx1-Cre [29]. As in E/F+/- Mx1-Cre+ mice, 
spleen cells were enriched for CD43+/CD71+/CD117+/
CD45- cell populations (Supplementary Figure S8C). 
Although Osx-Cre mainly targets osteoblast progenitors, 
it has also been shown to target non-osteoblast lineage 
cells in the bone marrow, such as stromal cells, adipocytes 
and perivascular cells [41]. Therefore, it is possible that 
EWS-FLI1 is expressed in the hematopoietic lineage 
and induces leukemia in E/F+/- Osx-Cre+ p53fl/+ pRbfl/+ 
mice as the result of leakiness of the Osx-Cre system. 
Alternatively, extracellular vesicle-mediated systemic 
Cre mRNA exchange may have occurred between 
osteoblast progenitor cells with the active Osx promoter 
and hematopoietic cells that would not otherwise express 
Cre [42].
EWS-FLI1 expression in osteoblasts via the Col1a1 
promoter (Model #3Col1a2.3Cre-EF & Col1a3.6Cre-EF)
This mouse model was created by knocking-
in (KI) the human FLI1 cDNA (spanning exons 5-9) 
with a C-terminal FLAG epitope into mouse Ews exon 
Figure 1: Postnatal expression of EWS-FLI1 in cells with the activated Osterix promoter in E/F+/- Osx-Cre+ mice with 
or without p53 and pRb deletion in Model #2OsxCre-EF. A. Representative presentation of deformed nasal bone of an E/F+/- Osx-
Cre+ mouse compared to an E/F+/- littermate control. B. X-ray imaging of an E/F+/- Osx-Cre+ mouse showing structural abnormalities in 
facial bones as compared to the clear facial bone structure of an E/F+/- littermate control. C. Representative photographs of spleens and 
livers collected from E/F+/- p53fl/+ pRbfl/+ (control) and E/F+/- Osx-Cre+ p53fl/+ pRbfl/+ littermates. Hepatomegaly and splenomegaly were 
consistently observed in E/F+/- Osx-Cre+ p53fl/+ pRbfl/+ mice displaying leukemia-like symptoms. D. Kaplan-Meier survival plots for the 
indicated genotypes: E/F+/- p53fl/+ pRbfl/+ (n = 15); E/F+/- Osx-Cre+ p53fl/+ pRbfl/+ (n = 31); and Osx-Cre+ p53fl/fl pRbfl/fl, (n = 54) mice with 
doxycline diet until weaning age. In addition, survival plot for Osx-Cre+ p53fl/fl pRbfl/fl (n = 80) mice with no doxycycline diet is presented. 
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7 (Supplementary Figure S9 and [16]). This approach 
closely mimics the translocation found in patients, as 
EWS-FLI1 is expressed under the control of native Ews 
promoter/enhancer elements. A loxP-flanked STOP-
cassette was inserted in the antisense direction in Ews 
intron 6 to permit the conditional expression of EWS-
FLI1 [see [16] for details]. The constitutive expression 
of EWS-FLI1 using an EIIa-Cre mouse failed to produce 
any viable pups [16]. To prevent cytotoxic effects and to 
direct EWS-FLI1 expression to osteogenic progenitors, 
we crossed an Ews-FLI1KI mouse to two transgenic Cre 
mice: Col 3.6-Cre and Col 2.3-Cre [43]. These transgenic 
lines direct Cre recombinase expression to the osteoblast 
lineage using 2.3-kb (Col 2.3-Cre) and 3.6-kb (Col 3.6-
Cre) fragments of the rat Col1a1 promoter. Additional 
Cre expression in tendons was reported in the Col 3.6-Cre 
mouse only. Upon genotyping the pups at weaning and 
also at birth (more than 100 combined), no mice carrying 
both the Ews-FLI1KI and Cre genes could be obtained, 
suggesting embryonic lethality resulting from EWS-FLI1 
expression in osteoblast progenitors. Alternatively, low but 
detectable expression of Cre in non-osseous tissues of the 
Col 2.3-Cre and Col 3.6-Cre mice (such as the kidney, 
liver and skin) [43] might have resulted in embryonic 
lethality.
Transgenic approaches: ubiquitous or neuronal 
tissue
Ubiquitous expression of EWS-FLI1 via the EWS or 
Pgk promoter (Model #4Cosco-EF and Model #5Pgk-EF) 
We tried expressing EWS-FLI1 under broad and 
highly active promoters in transgenic mouse models to 
Figure 2: In vitro and in vivo expression of EWS-FLI1 and luciferase in Model #10COMET and COMETΔNeo. A. Western blotting 
against EWS-FLI1 and beta-actin was performed in triple-transfected (COMET + Cre + rtTA) 293T cells treated with increasing amounts 
of doxycycline (DOX). The A673 ES cell line is shown as the positive control for endogenous EWS-FLI1 expression (right lane). B. The 
COMET construct was transiently co-transfected in vitro with (+) or without (-) Cre recombinase and rtTA and in the presence or absence 
of DOX. Varying amounts of DOX (0 to 1,000 ng/ml) were added to the media. C. Models #10COMET (left) #10COMETΔNeo (right) chimera 
were imaged for in vivo luminescence measurements. D. Quantitative RT-PCR for EWS-FLI1 and luciferase in #10COMET (left panel) and 
#10COMETΔNeo (right panel) expression in various organs extracted from the imaged mice in panel C. Relative expression (to testis expression 
level) of duplicates with respective SD is shown.
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recapitulate the human ES phenotype. A cosmid containing 
the EWS promoter and the full EWS-FLI1 gene fusion 
were transfected into murine embryonic stem cells. We 
generated chimeric mice, but we were not able to obtain 
stable transgenic founder animals in the F0 generation 
(Supplementary Table S2, Supplementary Figure S10). 
We also tried expressing EWS-FLI1 under the control 
of a murine phosphoglucokinase-1 (Pgk-1) promoter 
(Supplementary Table S2, Supplementary Figure S11). We 
obtained two female F0 chimeric mice with the transgene, 
although one female was sterile and the progeny of the 
fertile mother were negative for the transgene.
Expression of EWS-FLI1 in neuronal tissues (Model 
#6Nse-EF and Nse-EF-SV and Model #7NEFL-EF)
As some ES cells express neuronal markers, 
including neuron-specific enolase (Nse), we prepared 
two transgenic constructs with the murine Nse promoter: 
one contained the EWS-FLI1 cDNA with the FLI1 
polyadenylation site (Nse-EF), and the other contained the 
SV40 polyadenylation site (Nse-EF-SV). We transfected 
these two transgenes into murine embryonic stem cells 
to generate chimeric mice (Supplementary Table S2, 
Supplementary Figure S12). Among 32 chimeras we 
created for each model, only one Nse-EF chimera was 
transgenic, but no F1 was obtained from this founder. 
This result raised the hypothesis of embryonic toxicity in 
strains where EWS-FLI1 is expressed under constitutive 
(EWS, Pgk) or highly active (Nse) promoters. To overcome 
this problem, we expressed EWS-FLI1 under a minimally 
active neuron-specific promoter, neurofilament light chain 
(NEFL), as this gene was reported to be expressed in ES 
cells [44]. In Model #7NEFL-EF, we used the human NEFL 
promoter to drive the expression of EWS-FLI1 in mice 
(Supplementary Table S2, Supplementary Figure S13). 
Interestingly, four transgenic lines were obtained with 
Mendelian inheritance of the transgene. RT-PCR for the 
EWS-FLI1 transcript confirmed its specific expression 
in adult brain tissues (Supplementary Figure S13), but 
no tumor development was observed in these mice even 
after long-term surveillance (>1 year). This transgenic 
model may have expressed EWS-FLI1 too late in cellular 
differentiation to cause the growth of an embryonic tumor 
because NEFL is only expressed in post-mitotic neurons 
[45].
Inducible expression of EWS-FLI1 via ubiquitous 
promoters (Model #8 MT-EF, and Model #9PLAPtTA-EF)
In order to gain better control over the timing 
of EWS-FLI1 expression, we tried different inducible 
promoter systems. The metallothionein (Mt) promoter, 
which induces expression of a transgene upon 
administration of ZnCl2 to mice, was used to promote 
EWS-FLI1 expression in Model #8MT-EF (Supplementary 
Table S2, Supplementary Figure S14). Four stable 
transgenic lines were obtained. After ZnCl2 administration 
to the mice (24 h up to several weeks), various tissues 
were collected, but EWS-FLI1 expression was not 
detected in any of the tissues. We also used a tet-off 
system to control EWS-FLI1 expression (Supplementary 
Table S2, Supplementary Figure S15). In order to 
conditionally induce CMV-driven EWS-FLI1 expression 
upon doxycycline removal, two stable pUHD-10.3-
EF strains were backcrossed with the LT1 strain that 
expresses the tetracycline-controlled transactivator 
(tTA) under the control of the human placental alkaline 
phosphatase (PLAP) promoter. Unfortunately, none of 
these backcrosses (Model #9PLAPtTA-EF) gave rise to double 
transgenic mice. 
Spatiotemporal regulation of EWS-FLI1 expression 
(Model #10COMET and COMETΔNeo)
Learning from our past unsuccessful attempts 
(Supplementary Table S2) and from others [15, 16, 28, 
29], we aimed to generate an inducible and conditional 
transgenic EWS-FLI1 mouse model. We created a knock-
in (Gt(ROSA)26Sor locus) Cre/lox tetO inducible Mouse 
model for Ewing Tumor (COMET) (Supplementary Figure 
S16). For the conditional approach, an antisense EWS-
FLI1 cassette was flanked with single mutated Lox sites 
(Lox66, Lox71). Upon Cre-mediated recombination, EWS-
FLI1 is reversed and maintained in the sense orientation 
due to the generation of a double mutated lox72 site 
(unrecognized by the Cre) and a loxP site [46]. For the 
inducible strategy, a tet-On cassette containing a TREtight-
inducible promoter oriented in the antisense direction 
was introduced in the Gt(ROSA)26Sor locus, as this was 
reported to improve its inducibility in this locus [47]. In 
order to track EWS-FLI1 expression using noninvasive 
bioluminescence imaging, an IRES luciferase (IRES Luc) 
cassette was added downstream of EWS-FLI1. A Frt-
flanked neomycin selection cassette was also added. All 
of these cassettes were finally cloned into the pROSA26-1 
vector to generate a pROSA26-1-COMET construct 
(Supplementary Figure S16). Western blotting against 
EWS-FLI1 (Figure 2A) confirmed the functionality 
of the COMET construct in vitro by co-transfecting a 
combination of COMET, Cre and rtTA plasmids in the 
presence or absence of doxycycline. Chemiluminescence 
only detected IRES-driven luciferase expression in the 
cells transfected with the COMET, Cre and rtTA constructs 
in a doxycycline dose-dependent manner (Figure 2B). 
To generate Model #10COMET and COMETΔNeo, a knock-in 
strategy into the well-characterized Gt(ROSA)26Sor locus 
was favored over classical transgenesis (Supplementary 
Figure S16) due to its permanent accessibility for 
transcriptional activation in mice [48]. Homologous 
recombination was performed in murine embryonic stem 
cells with the pROSA26-1-COMET construct, and two 
positive clones (2C12, 2D8) were confirmed by Southern 
blotting (Supplementary Figure S17). We injected 
these two clones into mouse blastocysts. Among seven 
chimeric mice, only three generated agouti F1. However, 
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none of the 31 F1 agoutis contained the COMET allele 
(Supplementary Table S3). This led us to speculate about 
the possible leaky expression of EWS-FLI1 leading to 
toxicity in Model #10COMET chimeric tissues. To overcome 
a described bidirectional activity of the PGK promoter that 
may have led to EWS-FLI1 expression [49], embryonic 
stem cell clones, 2C12 and 2D8, were transiently 
transfected with the pCAGGS-Flpe plasmid in order to 
delete the PGK-Neo selection cassette through FLPe/
FRT-mediated excision (Supplementary Figure S16). 
Two clones deleted for the PGK-Neo cassette (1C3, 2A4) 
were injected into mouse blastocysts, giving rise to seven 
Model #10COMETΔNeo chimeric mice. Unfortunately, none of 
the 33 F1 agoutis contained the Model #10COMETΔNeo allele 
after backcrossing (Supplementary Table S3).
To determine whether the manipulated genetics 
of both the Model #10COMET and Model #10COMETΔNeo 
chimeric mice were functioning as designed, we measured 
bioluminescence. A clear signal was detected in the testes 
of both chimeric mouse models (Figure 2C). RNA from 
various organs of these chimeric mice was extracted, 
and RT-qPCR experiments for the expression levels of 
luciferase and EWS-FLI1 were performed (Figure 2D). 
The highest expression level of luciferase was found in the 
testis and correlated with EWS-FLI1 expression. In Model 
#10COMET, comparable mRNA levels were detected in the 
testis and spleen. However, bioluminescence was absent 
in the spleen (Figure 2C, white arrow), indicating that the 
protein may not be correctly processed in this organ.
To investigate the underlying cause of the leaky 
EWS-FLI1/luciferase expression, various organs were 
collected from Model #10COMET and COMETΔNeo chimeric mice. 
As untranslated transcripts of the Gt(ROSA)26Sor locus 
are expressed at high levels in the epididymis and the 
testis, we evaluated whether the EWS-FLI1/luciferase 
transcript might be expressed from the Gt(ROSA)26Sor 
promoter. In Model #10COMET chimeric mice, using RT-
PCR, a fusion transcript between part of exon 1 of the 
RNA-gene trap ROSA 26 transcript (NR_027009.1) 
and the PGK promoter was detected only in the testis 
(Supplementary Figures S18A and B). However, this 
fusion transcript was expressed at very low levels and may 
have accounted for only a fraction of the high luciferase 
expression detected in the testes of Model #10COMET mice. 
In Model #10COMETΔNeo chimeric mice, a fusion transcript 
between exon 1 of the RNA-gene trap ROSA 26 transcript 
and the lox71 site (located just upstream of EWS-FLI1) 
could be detected in various organs (Supplementary 
Figures S18C and D). This fusion transcript was 
much more abundant than that was detected in Model 
#10COMETΔNeo mice and may have therefore accounted for a 
substantial part of the high luciferase expression detected 
in the testes of Model #10COMETΔNeo mice. 
Transgenic approaches: mesenchymal tissue
EWS-FLI1 expression in early limb bud mesenchyme 
via the Prx1 promoter (Model #11Prx1Cre-EF)
In parallel to using Cre driven by the Col1a1 
promoter, we also targeted the expression of EWS-
FLI1 to the early limb bud mesenchyme using Prx1-Cre 
transgenic mice (Supplementary Figure S19 and [50]). 
Again, no viable EWS-FLI1; Prx1-Cre positive pups 
were obtained at birth (more than 100 genotyped). Lin 
et al. reported using the same Prx1-Cre mouse to drive 
EWS-FLI1 expression in 3 transgenic lines [28]. These 
authors reported severe limb development defects in 
E14.5 embryos and embryonic lethality in one of their 
transgenic lines (EF-c), while two other transgenic lines 
showed milder limb deformities and a normal life span. 
Because the expression of EWS-FLI1 in our model was 
driven by the native EWS promoter, we speculated that 
the high levels of EWS-FLI1 expression in the early limb 
bud mesenchyme may have caused severe developmental 
defects in the limbs leading to embryonic lethality.
To circumvent the embryonic lethality of EWS-
FLI1, in an earlier study, we crossed an EWS-FLI1KI 
mouse with a transgenic mouse expressing Cre fused to 
a mutated estrogen receptor driven by the CAG promoter 
(B6.Cg-Tg(CAG-Cre/Esr1)5Amc/J, Jackson Laboratory). 
Mice carrying both EWS-FLI1 and CreER genes were 
viable and healthy. However, the induction of EWS-FLI1 
expression with tamoxifen led to the rapid death of the 
mice, demonstrating the cytotoxic effects of EWS-FLI1 
even in somatic cells [16]. Collectively, these results 
highlight the difficulty in generating an ES mouse model 
and the importance of limiting EWS-FLI1 expression to 
a permissive cell type (presumed to be the EWS-FLI1 
expression-tolerant tumor cell of origin).
Somatic chromosomal translocation between 
endogenous EWSR1 and FLI1 loci in mesenchymal 
and neural crest tissue (Model #12Cre-TL-EF)
We targeted mouse embryonic stem cells to insert 
a single loxP site into the Ewsr1 locus and a single loxP 
site into the Fli1 locus (Supplementary Figure S20). 
To avoid the potential loss of germline transmission, 
we chose to generate two separate strains instead of a 
single embryonic stem cell line in which both loci were 
targeted. This approach allowed us to delete the selectable 
markers prior to breeding the Ewsr1- and Fli1-targeted 
mice together without concern for extemporaneous 
recombination events. Ewsloxpurolox mice were made by 
inserting a lox-puromycinr-lox cassette between exons 8 
and 9 of Ewsr1 on chromosome 9. Embryonic stem cell 
clones surviving puromycin selection were screened by 
Southern blot analysis for correct targeting (Figure 3A). In 
addition, Southern blot analysis allowed for a comparison 
between the intensities of the targeted Ewsloxpurolox and the 
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non-targeted WT alleles in order to select clones that were 
likely to have a single targeted and single non-targeted 
Ewsr1 allele. We used a similar approach to generate 
the Fli1loxhygrolox mice. A lox-hygromycinr-lox cassette was 
inserted into the Fli1 locus on chromosome 11, between 
exons 5 and 6 (Supplementary Figure S20). As before, 
Southern blots were used to confirm correct targeting 
(Figure 3B). Targeted embryonic stem cells (from non-
albino C57BL/6 cells) were injected into albino C57BL/6 
blastocysts to generate chimeric mice. Once we obtained 
chimeras with suspected germline chimerism, we bred 
them to albino C57BL/6 mice and screened black pups for 
the presence of the lox-flanked cassettes. Mice carrying 
the cassettes were then bred to a CMV-Cre strain, in which 
Cre is expressed during implantation of the developing 
embryo [51]. Early Cre expression resulted in the deletion 
of the selection cassettes and the generation of mice 
with a single lox site in the middle of the Ewsr1 locus 
(Ewslox/wt) and in the middle of the Fli1 locus (Fli1lox/
wt), which was confirmed by genomic DNA sequencing 
(Supplementary Figure S21A). Ewslox/wt and Fli1lox/wt mice 
were bred to generate homozygous Ewslox/lox and Fli1lox/
lox mice (Supplementary Figure S20). These homozygous 
mice were used to generate all of the mice needed for the 
following experiments.
To test the feasibility of a reciprocal translocation 
event between chromosomes 9 and 11 in vivo, we 
first verified in vitro that this event could occur. Timed 
breedings between Ewslox/lox and Fli1lox/lox mice were 
set up to isolate mouse embryonic fibroblasts (MEFs). 
Figure 3: Somatic chromosomal translocation between endogenous Ewsr1 and Fli1 loci in Model #12Cre-TL-EF. A. Targeting 
mouse embryonic stem cells to insert a lox-puromycinr-lox cassette between exons 8 and 9 of the Ewsr1 locus. Genomic DNAs from the 
embryonic stem cell clones were EcoRI/AgeI (left) or KpnI (right) digested and were analyzed for the 5’ and 3’ integrations using Southern 
blot. Green and purple horizontal bars represent the probes used in the Southern blots. B. Targeting mouse embryonic stem cells to insert 
a lox-hygromycinr-lox cassette between exons 5 and 6 of the Fli1 locus. Genomic DNAs from the embryonic stem cell clones were ApaI 
(left) or EcoRV/KpnI (right) digested and were analyzed for the 5’ and 3’ integrations using Southern blot. Green and purple bars represent 
the probes used in the Southern blots. C. Schematic illustration for adenoviral Cre infection of Ewslox/wt; Fli1lox/wt MEFs in vitro. Genomic 
PCR was used to detect the translocated and untranslocated Ews and Fli1 chromosomes. The locations of the primers used are presented 
in the schematic. D. qPCR for Ews-Fli1 on total RNA from adenoviral Cre-treated MEFs. Hprt was used as the control gene, and samples 
were normalized to uninfected MEFs. 
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These Ewslox/wt; Fli1lox/wt MEFs were treated in vitro with 
adenovirus expressing Cre recombinase (Ad-Cre) (Figure 
3C). PCR analysis using primers from the Ewsr1 and 
Fli1 introns from Ad-Cre-treated MEF genomic DNA 
confirmed that the recombination event could take place 
(Figure 3C). The presence of both the WT and lox alleles 
for Ewsr1 and Fli1 demonstrated that the recombination 
event was not 100%, which was as expected based on 
published models using this system in mice (Figure 3C). 
The Ews-Fli1 and Fli1-Ews junctions were sequenced to 
confirm that the single lox site was flanked by genomic 
DNA from each chromosome. To determine whether the 
Ews-Fli1 gene was transcribed into Ews-Fli1 mRNA, qRT-
PCR was performed using primers that would span Ewsr1 
exon 8 to FLI1 exon 6. Ews-Fli1 mRNA was detected in 
the MEF lines treated with Ad-Cre (Figure 3D). The Ews-
Fli1 cDNA was then cloned using two rounds of nested 
PCR and sequenced to verify the correct splicing between 
Ewsr1 and Fli1. The CT values for the qPCR were 
relatively high, suggesting that Ews-Fli1 was expressed 
at a very low level. This low level of Ews-Fli1 expression 
may have resulted from the Ad-Cre infection; however, 
the batch of Ad-Cre had been used routinely in the lab 
to recombine lox sites found on a single chromosome 
with very high efficiency. Alternatively, the low level 
of detected Ews-Fli1 expression may have resulted 
from the loss of the cells expressing the translocation 
due to toxic effects. Attempts to quantify the levels of 
recombination using fluorescent in situ hybridization 
probes for chromosomes 9 and 11 were unsuccessful. 
However, given that the qPCR results confirmed that the 
translocation could be expressed, we hypothesized that 
even this low level of expression might be sufficient to 
initiate tumorigenesis in vivo. 
To establish a physiologically relevant mouse model 
of ES, the Ewslox/lox; Cre+ and Fli1lox/lox colonies were 
Figure 4: Histopathological analysis of tumors from Model #13RetroLTR-EF and Model #14piggyBac-EF. A. Fibrosarcoma developed 
in Model #13RetroLTR-EF. The storiform pattern of spindle-shaped, pleomorphic tumor cells is remarkable. Frequent mitotic figures (arrows) 
indicate aggressive tumor growth (left). α-SMA is a marker of smooth muscle and myofibroblastic cells. Human fibrosarcoma stains 
positive for α-SMA, whereas ES stains negative (middle). Expression of EWS-FLI1 in tumor tissue was confirmed using an anti-FLAG 
M2 antibody (right). B. Fibrosarcoma with a similar histology as (A) was also induced in Model #14piggyBac-EF. Invasive growth of the tumor 
in lung tissue is noted (left). PDGF-RB is a mesenchymal marker that is frequently positive in human fibrosarcoma and negative in ES 
(middle). The expression of EWS-FLI1 was confirmed by western blotting (right).
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crossed to generate cohorts of mice to observe for tumors 
over their life span. The mice in the experimental cohorts 
were Ewslox/+; Fli1lox/+; Cre+, and those in the control 
cohorts were Ewslox/+; Fli1lox/+; Cre-. We used 5 different 
Cre strains to generate tumor study cohorts: Col1a2-Cre 
(Cre+ n = 16, Cre- n = 6), Dermo1-Cre (Cre+ n = 25, Cre- n 
= 18), P0-Cre (Cre+ n = 20, Cre- n = 15), Prx1-Cre (Cre+ n 
= 25, Cre- n = 24), and Sox9-Cre (Cre+ n = 21, Cre- n = 15). 
Dermo1-Cre mice crossed with a LacZ reporter showed 
expression in mesenchymal tissues as early as E9.5; later, 
expression was detected in the condensing mesenchyme, 
chondrocytes and osteoblasts [52]. Col1a2-Cre showed 
a broader staining pattern than Dermo1-Cre, as LacZ 
expression was found starting around E8.5 in all dermal 
cells of the mouse as well as in the chondrocytes and 
osteoblasts of the developing bones [53]. The expression 
of Prx1-Cre began around E10 in the undifferentiated 
mesenchyme of the developing limb buds, increasing in 
expression with the development of the limb buds, in the 
mesenchyme between the limbs, and in the non-neural 
mesenchyme in the brain [50]. Some Prx1-expressing 
cells later expressed Sox9-Cre, giving us a subpopulation 
of Prx1-Cre cells to study [54]. The cells derived from 
the Sox9 lineage in the limb bud include chondrocytes 
and osteocytes, the cells that form tendons as well as the 
synovium (the soft tissue that lines the joints). A caveat of 
Sox9-Cre is that it has been shown to be expressed more 
broadly in various organ progenitor populations. To test 
whether a neural crest stem cell is the cell of origin for ES, 
we used the P0-Cre strain to drive Cre expression during 
the development of the neural crest lineage [55]. P0-Cre 
expression was shown to begin as early as E9.0 in tissues 
derived from the neural crest, and later in development, 
P0-Cre expression spread to the tissues derived from 
migrating neural crest cells. The notochord, which is 
not derived from the neural crest, also showed positive 
expression. 
In addition to the above tumor study cohorts, a 
smaller cohort using CMV-Cre mice was observed to 
test whether the Cre expression that occurred very early 
in the developing embryo would show an embryonic 
lethal phenotype or a tumor phenotype [51]. Whereas 
Dermo1-Cre and Col1a2-Cre bred to E/F mice resulted in 
embryonic lethality, we obtained mice born at Mendelian 
ratios for all Cre strains without any lethality [29]. All of 
the CMV-Cre+ (n = 12) and CMV-Cre- (n = 9) mice were 
observed for >80 weeks without any differences. For the 
tumor cohorts with the mesenchymal and neural crest 
Cre strains, no signs of tumorigenesis were apparent after 
70 weeks, so the cohorts were euthanized for analysis. 
Unfortunately, there were no differences between any 
of the Cre+ cohorts compared to the Cre- cohorts, and no 
obvious macroscopic tumors reminiscent of sarcomas 
were found (Supplementary Figures S22A-C). These 
results suggested either (i) the single hit of EWS-FLI1 
expression in a subset of cells was not sufficient to induce 
tumor formation in the mouse (e.g. EWS-FLI1 might 
not have been expressed in enough cells to facilitate 
tumorigenesis) or (ii) the Ews-Fli1 translocation event 
never occurred in the first place. 
We have shown that the Ews-Fli1 reciprocal 
translocation event did not induce tumor formation when 
expressed in mouse tissues using specific Cre strains. To 
test whether the loss of the tumor suppressors Ink4a and 
Arf would enable tumor formation or whether EWS-FLI1 
was able to alter the tumors formed with Ink4a/Arf loss, 
cohorts of mice were generated such that Cre expression 
would delete the Ink4a/Arf locus as well as induce Ews-
Fli1 translocation. The main groups of this study consisted 
of mice with the genotype Ews lox/+; Fli1lox/+; Ink4a/Arfflox/
flox; Cre+, which were tested using the following Cre 
strains: Col1a2-Cre, Dermo1-Cre, P0-Cre, Prx1-Cre, or 
Sox9-Cre. The control mice lacked Cre (Ewslox/+; Fli1lox/+; 
Ink4a/Arfflox/flox; Cre-) or were hemizygous for the floxed 
Ink4a/Arf allele (Ewslox/+; Fli1lox/+; Ink4a/Arfflox/+; Cre- and 
Ewslox/+; Fli1lox/+; Ink4a/Arfflox/+; Cre+). In addition, cohorts 
of mice with the genotypes Ewslox/lox; Ink4a/Arfflox/flox; Cre+ 
and Ewslox/lox; Ink4a/Arfflox/flox; Cre- using Dermo1-Cre, 
P0-Cre and Prx1-Cre were generated to test the effects 
of Ink4a/Arf loss itself on tumorigenesis. Mice were 
observed until they appeared moribund or they reached 
the age of 70 weeks. The survival curves for these mice 
demonstrated that EWS-FLI1 did not enhance or change 
the tumor phenotype of these mice (Supplementary 
Figures S22D-F). A summary of the types of tumors and 
the number of mice with each type of tumor are presented 
(Supplementary Table S4). The loss of Ink4a/Arf alone 
either with or without EWS-FLI1 expression led to 
decreased survival of the mice such that the majority of 
the Ink4a/Arfflox/flox; Cre+ mice died earlier than the control 
mice. To confirm that EWS-FLI1 was not expressed in 
the tumors that developed in these mice, total RNA from 
tumor tissues was isolated and qRT-PCR for Ews-Fli1 was 
performed. By normalizing to a line that did not express 
mouse Ews-Fli1 and using a positive control for mouse 
Ews-Fli1 expression (mouse EWS-FLI1-overexpressing 
MEFs), we demonstrated that none of the tumors from the 
Ink4a/Arf tumor study expressed Ews-Fli1 at levels above 
background (Supplementary Figure S21B).
Expression of EWS-FLI1 in murine mesenchymal stem 
cells (MSCs) (Model #13RetroLTR-EF and Model #14piggyBac-
EF)
MSCs are characterized by self-renewal activities 
and multi-directional differentiation [56]. It was expected 
that the cellular plasticity of MSCs might help EWS-FLI1 
to function as a proper ES oncogene. We expressed EWS-
FLI1 in bone marrow-derived MSCs (BM-MSCs; [57]) 
using retrovirus- or transposon-mediated gene transfer. 
FLAG-tagged EWS-FLI1 was inserted into the pMYs-
IRES-Neo retroviral vector (Supplementary Figure S23). 
BM-MSCs of a BALB/c background were transduced with 
the retrovirus and then injected into sublethally irradiated 
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(8 Gy) BALB/c recipients via the tail vein. All recipients 
(n = 5) developed multiple tumors in the lungs three 
weeks after injection. Histologically, the tumors exhibited 
storiform growth of spindle cells with frequent mitotic 
figures, which was consistent with the characteristics of 
fibrosarcoma (Figure 4A). The EWS-FLI1 transposon 
construct was generated using the piggyBac (PB) 
transposon/transposase system [58] (Supplementary 
Figure S24). BM-MSCs were transfected with PB-EF 
along with mRNA of the piggyBac transposase to increase 
the transfection efficiencies. The transfectants were 
transplanted into irradiated recipients as above (n = 5) or 
transplanted subcutaneously (n = 9). Again, 100% of the 
recipients developed fibrosarcoma-like tumors within 8 
weeks (Figure 4B). Thus, although EWS-FLI1 expression 
could induce neoplastic transformation of BM-MSCs, the 
lesions did not recapitulate the morphologic characteristics 
of the small, round cells observed in human ES.
Non-transgenic approaches: localized Cre 
delivery
Localized Cre delivery via in vivo electroporation in 
EWS-FLI1 translocation mice (Model #15CreEP-TL-EF)
Localized expression of EWS-FLI1 was also 
tested in the Cre-loxP-mediated somatic chromosomal 
translocation model mice [30]. A Cre expression plasmid, 
pMC1-Cre, was delivered into the muscles of the 
lower legs of Ewsr1fl/+:Fli1fl/+ mice via electroporation 
(Supplementary Figure S25). The delivery of Cre via 
electroporation in vivo was successfully achieved to induce 
pleomorphic rhabdomyosarcoma in adult mice [59]. The 
mice received in vivo electroporation of the Cre plasmid 
four times and were observed for 1 year. No CreEP-TL-EF 
mice (n = 12) developed neoplastic lesions in the muscle, 
though the mice did show localized degeneration of the 
muscle fibers (Supplementary Figure S26), which was 
comparable to the damage in the myocardium in Cag-
Cre:Ewsr1fl/+:Fli1fl/+ mice [30].
Figure 5: Intramuscular and intraperitoneal delivery of adenovirus-Cre in 1-day-old E/F+/+ mice in Model #16Ad5Cre-EF. 
A. Penetrance of limping phenotype observed in Ad5-Cre-injected left leg vs. Ad5-eGFP-injected right leg (n = 11) at an age of 1 day. B. 
Comparison of quadriceps femoris muscle width between an Ad5-eGFP-injected right leg and Ad5-Cre-injected left leg. C. Representative 
image showing muscle atrophy observed in Ad5-Cre-injected leg. D. Penetrance of abdominal distention phenotype observed in 1-day-old 
mice IP-injected with Ad5-Cre (n = 9) vs. Ad5-eGFP (n = 7). E. Comparison of intestine length (from stomach to rectum) in 1-day-old 
mice IP injected with Ad5-Cre vs. Ad5-eGFP. F. Representative image showing shortened intestines observed in Ad5-Cre-injected mice 
compared to littermate mice of the same genotype injected with Ad5-eGFP.
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Localized adenovirus-mediated Cre delivery in E/F 
mice (Model #16Ad5Cre-EF)
Expressing EWS-FLI1 in most tissues resulted in 
embryonic lethality, as described in earlier models. To 
circumvent the reliance on tissue-specific promoters and 
to overcome embryonic lethality, we utilized adenovirus-
delivered Cre to allow for the localized expression of 
EWS-FLI1 at different stages of postnatal development 
in E/F mice (Supplementary Figure S27). Adenovirus-
Cre-mediated recombination has been successfully 
used to generate sporadic lung cancer [60], pancreatic 
adenocarcinoma [61], and colon cancer [62] mouse 
models. We hypothesized that the target cell may be 
present or susceptible to EWS-FLI1 tumorigenicity 
at certain stages of postnatal development. Therefore, 
adenovirus-Cre (Ad5-Cre) was delivered via intramuscular 
(IM), intraperitoneal (IP), or intravenous (IV) injections at 
different ages. 
For IM delivery, E/F mice were injected with 109 
plaque-forming units (pfu) Ad5-Cre in the left leg and 
109 pfu Ad5-eGFP in the right leg at 1 day, 1 week, or 2 
weeks of age. Cre mediated removal of the STOP-cassette 
48 h after IM delivery of Ad5-Cre was confirmed using 
genomic DNA PCR (Supplementary Figure S28A). We 
observed muscle loss, limping, and prolonged clasping of 
the hind leg in the Ad5-Cre injected leg, but not in the Ad5-
eGFP injected leg (Figure 5A and Supplementary Figure 
S28B). Significant muscle loss was observed in the Ad5-
Cre-injected left leg compared to the Ad5-eGFP-injected 
right leg of the same mouse, which was quantitated as the 
width of the quadriceps femoris muscle (Figures 5B and 
5C). EWS-FLI1 expression has been previously reported 
to induce caspase 3 transcription, which subsequently 
triggers apoptosis in vivo [16]. EWS-FLI1 expression 
in cultured cardiac muscle cells also induced apoptosis 
in vitro and cardiomyopathy in vivo [30]. Hence, the 
observed myopathy in the legs injected with Ad5-Cre may 
have been due to the apoptotic effect of EWS-FLI1 in 
the myocytes in which Cre-mediated recombination may 
have occurred. This phenotype was more evident in mice 
injected at day 1 postnatal compared to the mice injected 
at 1 or 2 weeks, in which the penetrance of the phenotype 
observed was 90.9%, 9.1%, and 11.1%, respectively 
(Figure 5A and Supplementary Figure S28C). This 
observation may have indicated a differential sensitivity 
of murine muscle cells to EWS-FLI1 expression during 
early postnatal development. Alternatively, the variability 
in the penetrance of the phenotype may have been 
because the dosage per body weight was much higher in 
the 1-day-old mice compared to the older mice injected 
with the same number of Ad5-Cre viral particles. None of 
the IM-injected mice developed sarcoma when they were 
observed up to 9 months of age. 
For IP delivery, E/F mice were injected with 109 pfu 
of Ad5-Cre at 1 day or 1 week of age. As the negative 
control, we used 109 pfu Ad5-eGFP injected littermates of 
the same age and genotype. Cre expression was confirmed 
48 h after IP delivery of Ad5-Cre-eGFP using Maestro 
fluorescence imaging (Supplementary Figure S29A). 
Three weeks following injection in 1-day-old mice, most 
of the Ad5-Cre mice presented with abdominal distention 
(Figure 5D and Supplementary Figure S29B). The Ad5-
Cre-injected E/F mice also showed significantly shortened 
small intestines (Figures 5E and 5F). Additionally, we 
observed malformed livers in the Ad5-Cre-injected mice; 
the liver had a more globular shape compared to the 
normal disc shape (Supplementary Figure S29C). The 
same phenotypes were present in the mice injected with 
Ad5-Cre at 1 week of age (Supplementary Figure S29D). 
The E/F mice intraperitoneally injected with Ad5-Cre at 
1 week of age survived up to 6 months, but none of them 
developed any detectable ES. Histopathological analysis 
of the intestines did not reveal any defects in the villi or 
crypt structures in the majority of the intestine, but there 
were small areas of necrosis and perforation in the wall in 
multiple locations in each mouse, which may have led to 
leakage into the peritoneal cavity that caused distention 
of the abdomen (Supplementary Figure S30). The growth 
arrest and apoptotic effects of EWS-FLI1 expression may 
explain the defects in small intestine development [14-16, 
63]. The ability of EWS-FLI1 to antagonize β-catenin/
TCF-mediated transcription may have also contributed 
to the shortened small intestine phenotype [64, 65]. 
Furthermore, as an effort to deliver Cre recombinase 
systematically, we injected 109 pfu Ad5-Cre intravenously 
in 3-week-old E/F mice; their littermates were injected 
with 109 pfu Ad5-eGFP as a control. Over 7.5 months 
of follow-up, neither the Ad5-Cre- nor the Ad5-eGFP-
injected mice presented with any evident phenotype. 
DISCUSSION
Several pediatric sarcomas contain tumor-specific 
chromosomal translocations that produce chimeric proteins 
with novel functions. These neoplasms include alveolar 
rhabdomyosarcoma, myxoid liposarcoma, synovial 
sarcoma, and clear cell sarcoma harboring PAX3:FKHR 
t(2;13), TLS-CHOP t(12;16), SYT-SSX t(X;18), and EWS-
ATF1 t(12;22) chromosomal translocations, respectively 
[22, 23, 66, 67]. Similar to the role of EWS-FLI1 in 
ES, both Pax3:Fkhr and SYT-SSX have been shown 
to play critical roles in the malignant phenotypes of 
rhabdomyosarcoma and synovial sarcoma cell lines, 
respectively. These observations led to development of 
useful transgenic mouse models for both tumors. When 
PAX3:FKHR expression was targeted by the Myf6 
promoter in terminally differentiating skeletal muscle, 
mice developed alveaolar rhabdomyosarcoma with a very 
low penetrance (< 1%). However, when the transgene 
was expressed on the Ink4a/Arf or p53 null background, 
the penetrance increased to 30-40% [24]. Similarly, the 
expression of the TLS-CHOP chromosomal translocation 
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product under the control of the Prx1 promoter (in early 
mesodermal tissue) induced myxoid liposarcomas only on 
the p53 null background [25]. Moreover, the expression 
of the EWS-ATF1 chromosomal translocation product in 
neural crest-derived cells resulted in clear cell sarcomas 
[26], and when SYT-SSX expression was induced in 
Myf5-expressing myoblasts, 100% of mice developed 
synovial sarcoma-like tumors [27]. Interestingly, the 
induction of SYT-SSX expression through Hprt-Cre, 
Pax3-Cre, or Pax7-Cre resulted in embryonic lethality, 
and SYT-SSX expression in Myf6-expressing myocytes 
or Myf6-expressing myofibers resulted in myopathy 
but no tumors. Therefore, tumor-specific chromosomal 
translocation products can produce specific types of 
sarcomas in mice when they are expressed at the right 
time, in the right cell population and, in some cases, with 
the help of deleting tumor suppressors.
The successes in developing clinically relevant 
mouse models for rhabdomyosarcoma, myxoid 
liposarcoma, clear cell sarcoma, and synovial sarcoma 
have not been translated to ES, regardless of an exhaustive 
series of modeling attempts. Several factors have 
contributed to the failure of developing an ES transgenic 
mouse model by expressing EWS-FLI1. In most cell 
types, the expression of EWS-FLI1 induces growth arrest 
or apoptosis [14-16, 63]. Our findings are consistent with 
the detrimental effect of EWS-FLI1 expression in sensitive 
tissues, as we repeatedly observed embryonic lethality 
or developmental defects. Cooperation from the loss of 
additional tumor suppressor genes was not observed in 
our experiments, demonstrating that the correct dosage 
and timing of EWS-FLI1 expression was not met in these 
models despite multiple efforts and protocols used. The 
loss of p53 and Rb or p16 and p19 did not result in ES 
formation in the presence of EWS-FLI1.
The exact cell of origin for ES remains uncertain, 
which further impairs our ability to target the correct 
ontologic cell at the correct developmental stage. Even 
though many publications support the hypothesis that 
MSCs may be the cell type of origin [17, 18, 68-71], the 
lack of lineage-specific promoters as well as a range of 
MSC phenotypes prevents targeting EWS-FLI1 expression 
in these cells. In our studies, we used several promoters 
(Model #11Prx1Cre-EF, Model #12Cre-TL-EF, Models #13RetroLTR-
EF and #14piggyBac-EF) that can target EWS-FLI1 expression 
in different mesenchymal tissues without any success in 
generating ES in mice. 
For Model #1, we concluded that the cells 
expressing high levels of Cre, which resulted in high 
EWS-FLI1 expression, did not survive. Following Cre-
induced recombination, cells either died by apoptosis or 
were cleared by the immune system. Bone development 
is a dynamic process, and normal cells with lost Cre and 
EWS-FLI1 expression overtook the proper development 
of bone structures. One possible explanation for our 
negative results with the E/F+/- Runx2-Cre+ lines could be 
that the binding of EWS-FLI1 onto the Runx2 promoter 
negatively regulates Runx2 activity, which could inhibit 
differentiation of mesenchymal cells [72]. One could 
assume that EWS-FLI1 down-regulates Runx2 at the 
transcriptional level, and this is consistent with the lack 
of Cre expression, which itself retains a certain degree of 
toxicity.
EWS-FLI1 expression driven by Col 2.3-Cre or 
Col 3.6-Cre proved fatal to developing embryos. The 
original study reported robust Cre activity in osteoblast 
progenitors in E18.5 to postnatal day 5 animals [43]. 
However, it is unknown whether Cre activity is detected 
earlier in development. Furthermore, low but detectable 
levels of Cre activity were reported in the non-osseous 
tissues of these mice, suggesting the possibility that non-
osseous EWS-FLI1 expression caused embryonic lethality. 
Targeted expression of EWS-FLI1 in the early limb bud 
mesenchyme (E9.5) with Prx1-Cre was also fatal. Based 
on the abundant EWS expression levels in most tissues, 
it can be surmised that the native EWS promoter drives 
the high level of EWS-FLI1 expression upon Prx1-Cre 
activation, leading to embryonic lethality. Embryonic 
lethality was also observed in the Prx1-Cre-driven EWS-
FLI1 transgenic line [28].
Accumulating evidence suggests that EWS-FLI1 
may support oncogenic phenotypes beyond its role as a 
DNA-binding transcription factor. Recent epigenomic 
studies have identified EWS-FLI1 as an epigenetic 
driver. Similarly to MYC, EWS-FLI1 may function as a 
transcriptional amplifier of gene expression by binding to 
open promoters of widely expressed genes; EWS-FLI1 
may also activate novel enhancers and superenhancers [73, 
74]. It is therefore possible that the tissue- or stage-specific 
chromatin accessibility to key genes of ES tumorigenesis 
differs between mice and men, thus vexing our attempts 
at modeling [75]. 
Alternative splicing is emerging as an important 
mechanism in carcinogenesis [76]. Alternative splicing of 
the same gene may result in two proteins with opposite 
functional roles. BCL2L1 and FAS Receptor (TNR6) are 
two examples that can create both pro-apoptotic and 
anti-apoptotic protein products as a result of excluding 
or including a specific exon. EWS-FLI1 interacts with 
key proteins in the splicing complex and regulates 
alternative splicing of a specific set of genes that do 
not always overlap with transcriptional target genes 
(FLI1 target genes) [77-81]. Therefore, EWS-FLI1 may 
function through regulating transcription of certain genes 
and regulating translation of a different set of genes. 
The homology between human and mouse genes does 
not always cover the alternative splicing sites. Due to 
differences in alternative splicing sites between mice and 
humans, the expression of EWS-FLI1 in human cells may 
potentially result in a different set of alternatively spliced 
products than the products in murine cells. If these sets 
of genes are critical for ES development, then creating an 
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ES model in mice by expressing EWS-FLI1 may not be 
possible. 
Another difference between the human and mouse 
genomes involves microsatellite sequences. EWS-
FLI1 regulates target gene expression through GGAA 
microsatellite response elements [82-84]. The number 
of GGAA microsatellite motifs and their distance to 
promoters significantly alter target gene expression 
[85-87]. Furthermore, recent findings indicate that ES 
patients preferentially carry the A risk allele (compared 
to T) of the rs79965208 single-nucleotide polymorphism 
(SNP). An ES genome-wide association study identified 
microsatellite susceptibility variants near the EGR2 gene. 
The increase in the length of GGAA microsatellites may 
therefore contribute to EWS-FLI1 oncogenesis [88], but 
this microsatellite and SNP are not conserved in mice. 
Therefore, even though the human and mouse genomes 
may have similar EWS-FLI1 target genes, their expression 
patterns may be completely different due to differences 
in GGAA microsatellite motifs between the human and 
mouse genomes. 
Human ES cells express high levels of cell surface 
protein CD99, which is routinely used for confirming 
diagnosis [89-92]. In addition to its diagnostic value, 
inhibition of CD99 expression or engagement by CD99 
antibodies stop growth of ES cell lines both in culture and 
in xenograft models [93-97]. Mouse homolog of CD99 has 
less than 50% amino acid identity to its human counterpart 
[98, 99]. Therefore, biological pathways regulated by 
human CD99 and mouse CD99 may show significant 
differences. Because human CD99 is a critical component 
of ES pathogenesis, it is possible that the lack of a 
comparable protein in mouse cells may be responsible for 
the lack of ES development from EWS-FLI1 expression. 
ES patients harbor a balanced chromosomal 
translocation, which generates two chimeric fusion genes, 
EWS-FLI1 and FLI1-EWS. Many researchers in the field 
could not detect expression of FLI1-EWS mRNA or 
protein in ES cell lines or human tumor samples. However, 
a recent publication provided data suggesting that FLI1-
EWS is expressed in ES cells and more importantly FLI1-
EWS expression is required for EWS-FLI1 mediated 
transformation [100]. If this hypothesis is true, the lack of 
FLI1-EWS component in our attempts might have been 
responsible for the failed mouse models . 
In summary, the ectopic expression of EWS-
FLI1 in murine MSCs, neural crest-derived stem 
cells, or osteochondrogenic progenitor cells could 
transform primary cells into malignant tumor cells. 
However, achieving tumor growth in animals with 
intact immune systems is a higher-level challenge than 
anchorage-independent growth or tumor development 
in immunocompromised mice with cells transformed 
in vitro. Hence, it remains possible that an EWS-FLI1-
driven sarcoma model can be generated, although the 
number of failed attempts at creating a transgenic model 
suggest that this challenge has yet to be accomplished. 
This comprehensive analysis of those models that have 
been attempted, without success, should allow future 
investigations to advance without repeating unsuccessful 
models. 
MATERIALS AND METHODS
All procedures involving mice were approved by the 
respective institutions’ animal care and use committees. 
Model #1Runx2Cre-EF
Mice were kept under standardized conditions at 
the Decentralized Biomedical Facility of the Medical 
University of Vienna. E/F mice harboring a Cre-inducible 
EWS-FLI1 knocked into the ubiquitous ROSA26 locus 
(ROSA26loxP-STOPloxP-HA-EWS-FLI1 allele) [29] 
were crossed to three different Runx2-Cre isoforms [35]. 
Runx2 was expressed from promoters p1 and p2 [101]. 
These strains were generated with a BAC (bacterial 
artificial chromosome) approach with different transgenic 
integrations and copy numbers (#777, #784, #1634). E/
F+/-Runx2-Cre+ mice were also bred to mice deficient in 
p16INK4A and p19ARF proteins [37]. All mice were on mixed 
background (Sv129 and C57BL/6).
Model #2OsxCre-EF
Mice
E/F mice were generously provided by Dr. S. Baker 
(St. Jude Children’s Research Hospital) and were on a 
C57BL/6 background. Osx-Cre mice on a C57BL/6J 
background were obtained from the Jackson Laboratories 
(Bar Harbor, ME). Osx-Cre+p53fl/fl pRbfl/fl animals were 
generously provided by Dr. Stuart Orkin (Harvard 
University) and were on a C57BL/6J 129 FVB/n hybrid 
background. E/F mice were maintained as homozygotes 
(E/F+/+) and bred with either Osx-Cre+ or Osx-Cre+p53fl/fl 
pRbfl/fl animals. Mice received doxycycline diet (2000mg/
kg diet, Harlan Laboratories) throughout the pregnancy 
(average 21 days) and withdrawn at the weaning age 
of pups (postnatal day 21). Mice were euthanized if the 
animals showed signs of pain and distress or when the 
animals reached the age of 300 days. 
Flow cytometry
For cell surface analysis of splenocytes, harvested 
spleens were minced into small pieces in 1x PBS to release 
the blood cells, which were subsequently strained using 
70 μm cell strainer (Fisher, Cat No. 352350) to prepare 
a single cell suspension. The strained mix was then 
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subjected to centrifugation at 350 g for 5 min. Pelleted 
cells were resuspended in 1x PBS and spleen cell count 
was determined using hemocytometer. 0.25 μl of CD43-
PE (Clone S11, BioLegend, Cat No. 143205), 0.5 μl of 
CD45-Alexa Fluor-488 (Clone 30-F111, BioLegend, Cat 
No. 103122), 1 μl of CD71-Brilliant Violet 421 (Clone 
RI7217, BioLegend, Cat No. 113813), and 2.5 μl of 
CD117-APC (Clone 2B8, BioLegend, Cat No. 105812) 
fluorescent conjugated primary antibodies were used to 
stain one million splenocytes in 100 μl 1x PBS for 20 min 
on ice in the dark. The stained cells were washed twice 
with 1x PBS. The cells were then resuspended in 500 μl of 
1x PBS and analyzed using flow cytometer. 
Western blot
Total protein extracts were prepared from spleens 
and livers of E/F+/- Osx-Cre+ p53fl/+ pRbfl/+ mice using the 
following protocol. Small fragments (~2mm3) of flash 
frozen spleens were homogenized using hand held mortar 
mixer (VWR, Cat. No: 47747-370) in 200 μl phospholysis 
buffer (50 mM HEPES pH 7.9, 100 mM sodium chloride, 
4.0 mM sodium pyrophosphate, 10 mM EDTA, 10 mM 
sodium fluoride, and 1% Triton X-100 v:v) containing 
2.0 mM sodium vanadate, 1.0 mM PMSF, 4.0 µg/ml 
aprotinin, and 4.0 µg/ml leupeptin. Once the spleens were 
fully homogenized, the lysates were incubated on ice for 
30 min. Next, the lysates were subjected to centrifugation 
for 10 min at 16,000 g at 4oC. Proteins were denatured 
in 5x Laemmli sample buffer and subjected to SDS-
PAGE (10% polyacrylamide). Resolved proteins were 
transferred to 0.45 μm Immobilon-P PVDF membrane 
(Millipore, Cat No. IPVH00010). The membranes were 
blocked in 5% nonfat dry milk in 1x TTBS (20 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 0.5% Tween 20 v:v) for 2 hrs. 
Dilutions for primary antibodies were anti-FLI1 (Santa 
Cruz Biotechnology, Cat No. sc-356) at 1:1000, anti-
HA (Roche, Cat No. 1867423) at 1:500, and anti-actin-
horseradish peroxidase (C-11, Santa Cruz Biotechnology, 
Cat No. sc-1615 ) at 1:5000. Primary antibodies were 
added to the membranes in 5% nonfat dry milk in 1x 
TTBS for 2hrs at room temperature. The membranes were 
then washed three times in 1x TTBS and incubated for 
1h with 1:5000 dilution of horseradish peroxidase-linked 
anti-rabbit (GE Healthcare, Cat No. LNA934V/AG) or 
anti-rat secondary antibody (R&D, Cat No. HAF005) 
prepared in 5% nonfat dry milk. Blots were washed three 
times in 1x TTBS and then developed using Immobilon 
Western Chemiluminescent HRP Substrate per the 
manufacturer’s instructions (Millipore Corporation, Cat 
No. WBKLS0100). Chemiluminescence was detected 
using a Fujifilm LAS-3000 imaging system.
RT-qPCR
RNA was extracted from ~50 mg flash frozen spleen 
fragments using TRIzol according to the manufacturer’s 
protocol (Invitrogen, Cat No. 15596-018). Extracted RNA 
was reverse transcribed to cDNA using QuantiTect reverse 
transcription kit (Qiagen, Cat No. 205311) as described by 
the manufacturer using Applied Biosytems Veriti Thermal 
Cycler. Real-time quantitative PCR was performed in 
an Eppendorf Mastercycler realplex using KiCqStart 
SYBR Green qPCR ReadyMix (Sigma-Aldrich, Cat No. 
KCQS00) per manufacturer’s protocol. Data were analyzed 
for expression relative to 18S rRNA using the comparative 
Ct method. Forward and reverse qPCR primers for 
EWS-FLI1 were CAGCCTCCCACTAGTTACCC and 
GTTGAGGCCAGAATTCATG, respectively. 
Model #3Col1a2.3Cre-EF and Col1a3.6Cre-EF and Model 
#11Prx1Cre-EF
Ews-FLI1KI mice (C57BL/6 background) had been 
described earlier [16]. Col1a2.3-Cre and Col1a3.6-Cre 
mice were generated previously [43] and Prx1-Cre mouse 
was purchased from Jackson Laboratory. Ews-FLI1KI mice 
were crossed with Col1a2.3-Cre, Col1a3.6-Cre or Prx1-
Cre and pups were genotyped at weaning and at birth 
(n>100 for each cross). No viable pups carrying both the 
EWS-FLIKI and Cre alleles were obtained in any of the 
crosses.
Models #4Cosco-EF, #5Pgk-EF, #6Nse-EF and Nse-EF-SV, #7NEFL-
EF, #8MT-EF, #9PLAPtTA-EF, and #10COMET and COMETΔNeo
Generation of the targeting vector and COMET mouse
The 6158 bp COMET cassette (Supplementary 
Figure S16) was gene synthetized (EpochBiolabs, INC. 
Missouri city, TX) and cloned into Sma1 digested pUC19. 
The resulting pUC19-COMET plasmid was digested 
with Nhe1, the resulting COMET cassette was subcloned 
into Xba1 digested pROSA26-1 vector (gift from P. 
Soriano). The resulting pROSA26-1-COMET plasmid 
was linearized using SacII and purified. This targeting 
construct was electroporated into CK35 (129 Stevens 
Pasteur background) mouse embryonic stem cells for 
homologous recombination. G418-resistant clones were 
isolated, screened by PCR for homologous recombination, 
and confirmed by southern blot (150 bp EcoR1/HindIII 
fragment of pROSA-5’, gift from P. Soriano). Two positive 
embryonic stem cell clones (2C12, 2D8) were injected 
into C57BL/6J blastocysts to generate the first generation 
of chimeras (Model #10COMET). FRT flanked Neomycin 
selection cassette was deleted in vitro by transient 
transfection of pCAGGS-Flpe (Gene Bridges GmbH, 
Heidelberg, Germany) plasmid into 2C12, 2D8 ES clone 
according to manufacturer protocol. The deleted subclones 
2A3 (derived from 2C12) and 1C3 (derived from 2D8) 
were injected into C57BL/6J blastocysts to generate the 
second generation of chimeras (Model #10COMETΔNeo).
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Quantitative RT-PCR
cDNAs were synthesized from 1µg of RNA 
using the GeneAmp RNA PCR core Kit (Applied 
Biosystem, Courtaboeuf, France). Quantitative PCR 
analyses were performed using SYBR green (Applied 
Biosystem). The following primers were used: EWS-
FLI1 (5’-GCCAAGCTCCAAGTCAATATAGC-3’, 
5’-GAGGCCAGAATTCATGTTATTGC-3’); 
luciferase (5’-TTACACGGCGATCTTTCCGCCC-3’, 
5’-AGTTGCGCGGAGGAGTTGTGTT-3’). 
Reactions were run on an ABI/PRISM 7500 (Applied 
Biosystem) and analyzed using the 7500 system SDS 
software. For detection of splice variant between 
Gt(ROSA)26Sor transcripts and COMET transcript, 
the following primers were used (EWSR1-kozac-Rev 
5’-TCCGTGGACGCCATGGTGAATT-3’,ROSA26-
EX1-Fw 5’-CTGCCGGGGCCGCCTAAAGAA-3’) with 
Phusion High-Fidelity DNA polymerase (Finnzymes, 
Finland); 35 cycles of 98°C for 7 seconds, 60°C for 20 
seconds, and 72°C for 30 seconds.
Luciferase assay
293T cells were plated into six well plates and 
grown in DMEM (Invitrogen, Cergy Pontoise, France) 
supplemented with 10% fetal calf serum. The day 
after, cells were CaCl2 transfected for six hours using 
1µg of pUC19-COMET alone and/or pIRES-Cre (Cre 
recombinase cloned into Xma1-Not1 digested pIRES) 
and/or pTet-On Advanced (Takara Bio Europe/Clontech, 
France) and 20 ng of pREP7-Rluc, (kindly provided 
by Keji Zhao). Twenty-four hours post-transfection, 
doxycycline (0 to 1000 ng/ml) was added to the media. 
Forty-eight hours post-transfection, cells were lysed and 
assayed for luciferase activity using the dual luciferase 
reporter assay system (Promega, Charbonnieres-les-bain, 
France) according to the manufacturer’s instructions. 
Firefly activity was normalized to Renilla luciferase 
activity to adjust differences in transfection efficiency.
Antibodies
β-actin antibody (A-5316) was purchased from 
Sigma-Aldrich (Saint-Quentin Fallavier, France). Anti-
FLI1 antibody (7.3) was described previously [102].
Noninvasive bioluminescence imaging
Approximately twenty minutes prior imaging, mice 
were injected intraperitoneally with 10 µl/g of body weight 
of sterile D-luciferin PBS solution (15 mg/ml). Mice were 
imaged using an IVIS Spectrum system (Caliper Life 
Sciences S.A., Villepinte, France) for 1 minute. Anesthesia 
was administered in an induction chamber with 2.5% 
isoflurane and reduced to 1.5% while the animal was in 
the IVIS imaging device. The data are reported as radiance 
(photons/sec/cm2/steradian).
Model #12Cre-TL-EF
Mice
Generation of Ewsloxpurolox/wt, Fli1loxhygrolox/wt and 
EWS-FLI1-V5 mice was carried out using standard gene 
targeting protocols. Correctly targeted embryonic stem 
cells were injected into albino C57BL/6 blastocysts by the 
Transgenic Facility at Stanford University. Southern blot 
analyses on embryonic stem cell clones were performed 
following standard protocols. Sox9-Cre, Dermo1-Cre, P0-
Cre and Col1α2-Cre mice were obtained from researchers 
that made the mice. Prx1-Cre mice were obtained from 
the Jackson Laboratory (B6.Cg-Tg(Prrx1-cre)1Cjt/J Stock 
Number: 005584). CMV-Cre mice were obtained from the 
Jackson Laboratory (B6.C-Tg(CMV-cre)1Cgn/J Stock 
Number: 006054). Ink4a/Arf floxed mice were a kind 
gift from Dr. Ron DePinho [103]. At the end of the tumor 
study, mice were euthanized and a necropsy was carried 
out. Gross abnormalities by eye were noted and chunks of 
tumors were collected and snap frozen in liquid nitrogen 
for future study. Tumors chunks were crushed cold using a 
mortar and pestle chilled by liquid nitrogen and the ground 
tissue was resuspended in Trizol. 
Cell culture
MEFs were isolated as following standard 
procedures from E13.5 embryos and cultured in DMEM 
with 10% BGS and 100U/100ug/2 mM Pen/Strep/
Glutamine (Invitrogen). Mouse bone progenitor cells were 
isolated as previously described and cultured in α-MEM 
supplemented with 20% fetal bovine serum (Omega 
Scientific) and 100U/100μg/2 mM Pen/Strep/Glutamine 
(Invitrogen) [104]. Adenoviral GFP or Cre infections were 
performed overnight in culture. Hematopoietic cells were 
isolated following standard protocols and immediately 
resuspended in TRIzol [105].
RNA analysis
RNA was isolated using TRIzol reagent (Invitrogen) 
following the manufacturer’s specifications. cDNA was 
synthesized using either the DyNAmo cDNA synthesis 
kit (New England Biolabs, F470) or the Maxima First 
Strand cDNA synthesis kit (Thermo, K1642). qPCR was 
performed using SYBR Green (Applied Biosystems). 
Primers
EWS lox genomic DNA 
TGGCCAGGCTATAAAACTACTTCCA   
       
TGCTGGGATGACTAGTTACAATTCC
FLI1 lox genomic DNA 
GTGACGGAGATCCCGAATTCTTTCC   
       
AACTGGGCCAGCCAACGCTTTC
EWS-FLI1 CAATATAGCCAACAGAGCAGCA  
GCTCCTCTCCTGACAGAGTCAT
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  GGGCAGCAGCCTCCTACTA  
TTCCATGCTCCTCTCCTGAC
HPRT   
TGACACTGGTAAAACAATGCA  
GGTCCTTTTCACCAGCAAGCT
Ink4a  
TGAGGCCGGATTTAGCTCTGCTC 
TCCGCTGCAGACAGACTTGCCAG 
Arf  
TGAGGCCGGATTTAGCTCTGCTC 
CTTGGTCACTGTGAGGATTC
Models #13RetroLTR-EF and #14piggyBac-EF
BM-MSCs were obtained from 6-week-old BALB/c 
mice (Crea Japan), according to the previously described 
method [57]. Self-renewal activities of BM-MSCs were 
confirmed by in vitro clonogenic assays, and differentiation 
into multiple lineages were confirmed by induction toward 
osteogenic, chondrogenic, neuronal, adipogenic and 
myogenic differentiation [56]. A FLAG-tagged EWS-FLI1 
was subcloned into pMYs-ires-neo retroviral vector, and 
retroviral packaging was carried out using PLAT-E cells (a 
gift from T. Kitamura). BM-MSCs were then transduced 
with the EWS-FLI1 retrovirus and injected from tail vein 
into irradiated BALB/c mice (model #13). EWS-FLI1 
was also subcloned into piggyBac transposon plasmid (a 
gift from P. Liu), and BM-MSCs were transfected with 
PB-EF and transposase mRNA generated by using an 
mMESSAGE mMACHINE T7 Ultra kit (Ambion). The 
cells were transplanted subcutaneously or injected via tail 
vein into irradiated recipients. Expression of EWS-FLI1 
was confirmed by western blotting using anti-FLAG M2 
and anti-beta-tubulin antibodies (Sigma).
Model #15 CreEP-TL-EF
Generation of Ewsr1fl/+:Fli1fl/+ mice (C57BL/6) 
was described elsewhere [30]. Genotypes of mice were 
confirmed by genomic PCR. The Cre expression vector 
pMC1-Cre (a gift by T. Yagi) was delivered by in vivo 
electroporation. The gastrocnemius muscles of 8-week-
old mice were injected with 50 µg of plasmid DNA, and 
the site of inoculation was immediately given electric 
pulses with a CUY21EDIT Square Wave Electroporator 
(NEPAGENE) using a CUY560-3 electrode. The pulse 
was 50 ms in duration at a voltage of 50V. Cre expression 
was confirmed 2 weeks after electroporation by RT-PCR.
Model #16Ad5Cre-EF
Mice
Both adenovirus-Cre (Ad5-CMV-Cre-eGFP) and 
adenovirus-eGFP (Ad5-CMV-eGFP) were purchased from 
University of Iowa Viral Vector Core Facility (Iowa city, 
IA). For intramuscular (IM) delivery E/F+/+ mice were 
injected with 20μl of 109pfu Ad5-CMV-Cre-eGFP in the 
left leg and 20μl of 109pfu Ad5-CMV-eGFP in the right 
leg at 1 day, 1 week, or 2 weeks of age using 31guage 3/8 
inch Thinpro insulin syringe (Terumo). For IP delivery, E/
F+/+ mice were injected with 20μl of 109pfu Ad5-Cre at 1 
day or 1 week of age. Littermate mouse of the same age 
and genotype were injected with 20μl of 109pfu Ad5-eGFP 
as a control. For IV delivery, 20μl of 109pfu Ad5-Cre was 
intravenously injected to 3 weeks old E/F+/+ mice. Their 
littermates were injected with 20μl of 109pfu Ad5-eGFP 
as a control. 
PCR
DNA extracted from E/F+/- and E/F+/+ mice livers 
were used as negative controls while DNA from leukemic 
E/F+/- Mx1-Cre+ mouse liver was used as a positive 
control. DNAs extracted from muscles of E/F+/+ mice 
injected with Ad5-eGFP in the right legs were also used 
as negative controls. DNA was isolated using wizard 
genomic DNA purification kit per manufacturer’s protocol 
(Promega, A1120) Extracted DNAs were subjected to 
PCR to confirm that Cre-mediated recombination has 
occurred. A forward primer located in the endogenous 
Rosa26 locus (GATCCACTAGTTCTAGAGCGGC) and 
a reverse primer that lies shortly after the first loxP site 
(GAGTTGTTATCAGTAAGGGAGC) were used to detect 
the knock-in allele. On the hand, the same forward primer 
in combination with a reverse primer that lies within the 
EWS-FLI1 sequence (GGTATCATAAGCACCAGTG) 
were used to detect the removal of the STOP-cassette. 
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